SARS-CoV-2 mRNA vaccine-Centre Hospitalier Universitaire de Nīmes-COVID-19

SARS-CoV-2 mRNA vaccine-Centre Hospitalier Universitaire de Nīmes-COVID-19 is an mRNA-based vaccine candidate evaluated by the Centre Hospitalier Universitaire de Nīmes for the prevention of COVID-19. The vaccine utilizes messenger RNA technology to encode the SARS-CoV-2 spike protein, specifically focusing on the receptor-binding domain (RBD). In the context of the VACTICOV2 clinical trial, researchers are investigating the physiological effects of the vaccine on monocyte production of reactive oxygen species (ROS) and lymphocyte apoptosis. The study explores the hypothesis that the circulating vaccine antigen may interact with the Angiotensin-converting enzyme 2 (ACE2) receptor, potentially reducing its enzymatic activity and modulating the Angiotensin II pathway, which could influence systemic inflammatory responses across different age groups.

Other names

anti-SARS-Cov-2 vaccinationanti-SARS-Cov2 vaccinationanti-SARS-Cov 2 vaccinationSARS-CoV-2 mRNA vaccine (CHU de Nîmes)COVID-19 mRNA vaccine (CHU de Nîmes)